AstraZeneca has agreed to purchase California-based respiratory medication developer, Pearl Therapeutics, in a deal with a total potential cost of up to $1.15bn. As per the definitive agreement signed between both the parties, AstraZeneca ...
Tags: AstraZeneca, Pearl Therapeutics
The US Patent and Trademark Office (USPTO) has granted a patent to Pearl Therapeutics' co-suspension formulation technology for inhaled combinations. The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl's ...